Influenza: Options to Improve Pandemic Preparation

Science and society have been struggling to find a way to protect humankind from recurring epidemics and pandemics of influenza. Here, we review the options available in the short term and also briefly address the solutions that research may make available in the long term.

[1]  G. Schild,et al.  A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. , 1975, Bulletin of the World Health Organization.

[2]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[3]  N. Cox,et al.  Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. , 2008, Vaccine.

[4]  S. Arifeen,et al.  Effectiveness of maternal influenza immunization in mothers and infants. , 2008, The New England journal of medicine.

[5]  M. Zambon,et al.  Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine , 2009, Proceedings of the National Academy of Sciences.

[6]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[7]  Hong Sun,et al.  Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. , 2009 .

[8]  K. Hoschler,et al.  Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.

[9]  X. de Radiguès,et al.  Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. , 2009, Vaccine.

[10]  Anthony S. Fauci,et al.  Influenza vaccines for the future. , 2010, The New England journal of medicine.

[11]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[12]  Xuguang Li,et al.  Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. , 2011, Vaccine.

[13]  Harish Nair,et al.  Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis , 2011, The Lancet.

[14]  J. Mascola,et al.  DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials , 2011, The Lancet Infectious Diseases.

[15]  T. Vesikari,et al.  Oil-in-water emulsion adjuvant with influenza vaccine in young children. , 2011, The New England journal of medicine.

[16]  D. Relman,et al.  Creating a mammalian-transmissible A/H5N1 influenza virus: social contracts, prudence, and alternative perspectives. , 2012, The Journal of infectious diseases.

[17]  P. Plans-Rubió.  The vaccination coverage required to establish herd immunity against influenza viruses. , 2012, Preventive medicine.

[18]  P. Palese,et al.  H5N1 influenza viruses: Facts, not fear , 2012, Proceedings of the National Academy of Sciences.

[19]  D. Pérez.  H5N1 Debates: Hung Up on the Wrong Questions , 2012, Science.

[20]  Yoshihiro Kawaoka,et al.  H5N1: Flu transmission work is urgent , 2012, Nature.

[21]  J. Belmont,et al.  Prior Infections With Seasonal Influenza A/H1N1 Virus Reduced the Illness Severity and Epidemic Intensity of Pandemic H1N1 Influenza in Healthy Adults , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  William G. Wadsworth,et al.  This copy is for your personal, non-commercial use only. , 2014 .